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Summary High dose metoclopramide is an effective anti-emetic for use with cisplatin containing chemo-
therapy regimens but can cause extrapyramidal reactions. Lorazepam and dexamethasone are increasingly
being used to alleviate chemotherapy induced emesis. This trial has assessed the contribution of high dose
metoclopramide to anti-emetic control when given with dexamethasone and lorazepam. Eighty-one patients
receiving chemotherapy, mainly for gynaecological malignancy, entered a randomised double blind cross-over
trial comparing dexamethasone and lorazepam with or without a 24 h metoclopramide infusion. This was
followed by oral dexamethasone with or without oral metocloproamide for three further days depending on
the initial randomisation. Sixty-one patients were fully evaluable. Fifty-five received cisplatin containing
regimens and six non-cisplatin regimens. There was a significant reduction in the number of episodes of
vomiting during the first 24 h in patients receiving the metoclopramide combination (P = 0.0001). On first
exposure to chemotherapy 45% of patients receiving dexamethasone, lorazepam and high dose metoclop-
ramide had no vomiting while 67% had two episodes or less ('major control'). This compared to 11% total
control and 25% major control in those receiving dexamethasone, lorazepam and placebo. The control of
nausea in the first 24 h was also improved (P = 0.0001), There was no difference in the degree of nausea or
vomiting during the following three weeks between those receiving oral dexamethasone alone and those
receiving dexamethasone and metoclopramide. Both groups showed a significant increase in nausea in the
three weeks following the second course of treatment when compared to the first (P = 0.0007). Extrapyramidal
reactions were recorded in 11.5% of patients receiving metoclopramide. More patients stated a preference for
the metoclopramide combination although this was not statistically significant (X21 = 0.29, P = 0.59). In
conclusion the combination of dexamethasone and lorazepam can give major control of emesis in 25% of
patients receiving very emetogenic chemotherapy. The addition of metoclopramide increases this to 67% on
first exposure to chemotherapy, but at the expense of extrapyramidal reactions in 11.5%.
From 1980 onwards the control of nausea and vomiting
became an urgent issue in parallel with advances made in
chemotherapy usage. Most notably the widespread use of the
potent emetogen cisplatin, particularly in testicular and
ovarian cancer, has caused an increase in the incidence of
emesis. The physical, psychological and sociological conse-
quences of such emesis in cancer patients are well described
(Coates et al., 1983).
Improved control of emesis has come from the better use
of anti-emetic agents; giving the drugs regularly, more fre-
quently and at higher doses (O'Brien & Cullen, 1988). Drugs
not previously used for anti-emesis have found an application
in this field and anti-emetic agents have been combined with
increased effect. High dose metoclopramide (Gralla et al.,
1981), lorazepam (Baker et al., 1979) and dexamethasone
(Allan et al., 1984) are all effective to some degree in the
control of chemotherapy induced emesis. However, there is
no single drug which offers reproducible efficacy for all forms
of chemotherapy.
In 1980 it was demonstrated that high doses of metoclop-
ramide could be given safely (Gralla et al., 1980). A blood
level of 850 ng ml-' ofmetoclopramide appeared to be neces-
sary for good control of cisplatin induced nausea and
vomiting (Meyer et al., 1984; Kerr et al., 1985). Not surpris-
ingly a loading dose followed by a maintenance infusion gave
more constant blood levels than intermittent administration
(Taylor & Bateman, 1983) and was associated with signi-
ficantly better control of nausea and vomiting and a reduc-
tion in diarrhoea (Warrington et al., 1986).
Although the glucocorticoids are not new drugs they have
only recently been used to control chemotherapy induced
emesis. There is no fixed regimen for such use but the
question of dose has been addressed in a prospective single
blind study in 22 patients, all receiving cisplatin, either alone
or in combination (Drapkin et al., 1982). Dexamethasone
was given intravenously starting at 8 mg and increasing by
8 mg increments to 40 mg with each alternative treatment
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cycle. In 17/22 there was no additional benefit from doses
above 8 mg.
Lorazepam was initially reported to be a useful adjunct to
anti-emetic treatment (Maher, 1981). It is now clear that it is
an effective anti-emetic in its own right and can help prevent
anticipatory vomiting (Bowcock et al., 1984).
In the management of emesis, agents with different
mechanisms of action are being combined in an attempt to
improve results and, if possible, decrease the incidence of
severe side-effects. As high dose metoclopramide is trouble-
some to give and can have permanent side-effects (Breitbart,
1986), this trial was designed to assess whether it conferred
any additional anti-emetic control when combined with high
dose dexamethasone and lorazepam during the acute period
when emesis most often occurs. The use of oral metoclop-
ramide in addition to oral dexamethasone was also assessed
in the prevention of delayed emesis.
Patients and methods
Patients aged less than 70 who were expected to receive at least
two courses ofchemotherapy necessitating 24 hours ofhospital
treatment, entered the study after giving signed, informed
consent. Patients who had previously received chemotherapy,
or in whom the study drugs were contraindicated, or who had
other medical causes for emesis, were excluded. The trial was
of standard double blind cross-over design with stratification
at entry according to whether patients were receiving cisplatin
or not. Patients randomised to group M/P received lorazepam,
dexamethasone and high dose metoclopramide (LDMet) dur-
ing their 24 h of chemotherapy followed by oral dex-
amethasone and oral metoclopramide for 3 days. Those ran-
domised to group P/M first received lorazepam, dex-
amethasone and placebo infusion (LDPlac) followed by oral
dexamethasone and placebo tablets for 3 days. Each group
crossed over to the alternative treatment during their second
course. Patients chose the anti-emetic regimen they preferred
for the third and subsequent courses.
The metoclopramide schedule of administration was deter-
'." The Macmillan Press Ltd., 1989 Br. J. Cancer (1989), 60, 759-763760 M.E.R. O'BRIEN et al.
mined after a pharmacokinetic study carried out in the hos-
pital on a similar population. The total daily dose was
10 mg kg'. LDMet consisted of 2 mg m2 lorazepam and
8 mg dexamethasone followed by 1 mg kg-' metoclopramide,
each made up in 50 ml of normal saline given i.v. over 10, 10
and 20 min respectively. The anti-emetics were commenced
50 min before the cisplatin infusion, or before the first emetic
chemotherapeutic agent. A 24 h infusion of metoclopramide
9 mg kg-' was then commenced using an infusion pump. In
addition, patients received dexamethasone 4 mg every 4 h i.v.
during the 24-h period. If there was no vomiting, patients
then received metoclopramide 20 mg q.d.s. and dexameth-
asone 4 mg q.d.s. orally for a further 3 days. LDPlac con-
tained the same doses of i.v. lorazepam and oral and i.v.
dexamethasone with placebo mini-infusion, placebo 24-h
infusion and placebo tablets. All chemotherapy was com-
menced in the evening and continued overnight.
Eighty-one patients were randomised. Two patients in
group M/P and four in group P/M were excluded after
randomisation for the following reasons: no available
infusion pump, 1; chemotherapy regimen longer than 24 h, 1;
protocol violation, 3; presence of renal failure, 1. Twelve
patients received only one course due either to death or to
withdrawal of chemotherapy due to disease progression, six
from each group. The patient characteristics are shown in
Table I and were equally distributed between the two arms.
The drugs used in combination with cisplatin were cyc-
lophosphamide, doxorubicin, ifosfamide, mitozantrone, mito-
mycin-C, bleomycin and etopside. The doses of cisplatin
ranged from 50-100 mgm2 and were similar in each arm.
The six non-cisplatin regimens consisted of ifosfamide or
cyclophosphamide with and without doxorubicin.
During the 24 h in hospital, data were collected hourly by
the nursing staff. The number of episodes of vomiting, the
volume of vomit, and retching and the level of consciousness
were documented. If patients were awake they were asked if
they felt nauseated. Any unusual reactions were recorded.
Patients then took home a diary card where they documented
each day the presence of vomiting, whether or not they felt
nauseated, their eating pattern and whether or not they were
able to carry out their normal activities.
Statistical analysis
The analysis of a two period cross-over trial is described by
Hills and Armitage (1979). In this design, there are three
effects of interest: 1(a) The treatment effect within patients,
ignoring course number. (b) The treatment effect during the
first period only. 2. The order effect, i.e. whether the result
was different between first and second courses, irrespective of
the treatment received. 3. The treatment vs order interaction,
i.e. whether any difference in effect between the two treat-
ments depends on the order in which they were given. The
tests for the order and treatment effect were based on cam-
parisons within patients and were the most powerful. The
test for interaction was based on a between patients com-
Table I Patient characteristics
LD Met LD Plac Total
Number of patients 33 28 61
Median age (years) 55 55
Range 24-69 27-69
Sex
Male 5 5 10
Female 28 23 51
Site of disease
Ovary 20 18 38
Other gynaecological 5 3 8
Germ cell 3 3 6
Lung 2 2 4
Other 3 2 5
Chemotherapy
Cisplatin + others 29 26 55
Non-cisplatin regimens 4 2 6
Mean cisplatin dose (mgm-2) 71 72
parison and was thus less sensitive. In addition, the effect of
treatment has been tested by comparing groups of patients
based on the first period alone.
Data for nausea and vomiting were not normally dist-
ributed thus tests of significance used the Mann-Whitney U
test. Data for total and major control of vomiting were
discrete so the procedures described by Hills and Armitage
(1979) for binary response data were followed, i.e.
McNemar's test was used for the order and treatment effects
and Fisher's exact test for the interaction and for the treat-
ment comparison within the first period.
Data on patient preference at the end of the second course
generated a 2 x 2 contingency table. Treatment vs order
interaction was assessed by the x2 test for association while
order and treatment effect were assessed by equality of the
marginal totals.
Results
Sixty-one patients received both treatments, 33 in group M/P
(LDMet first) and 28 in group P/M (LDPlac first). Data on
the first 24 h of treatment were available for all these
patients. Results for the three weeks following treatment are
based on 24 patients from group M/P and 20 from group
P/M who completed diary cards.
Figures 1 and 2 show the mean number of episodes of
vomiting and hours of nausea during the first 24 h, respec-
tively. Patients in group M/P experienced a mean of 2.7
episodes of vomiting when receiving LDMet with their first
course of chemotherapy. The same patients, when receiving
LDPlac with their second course of chemotherapy, experi-
enced a mean of 6.3 episodes of vomiting. Similarly, patients
in group P/M experienced a mean of 7.4 episodes ofvomiting
when receiving LDPlac with their first course of chemo-
therapy and 4.9 episodes when receiving LDMet with their
second course. There were no significant treatment vs order
interactions or order effects. LDMet was significantly more
effective both in the control of vomiting and in reducing the
number of hours of nausea.
Forty-five per cent of patients receiving LDMet during
their first course ofchemotherapy had total control of emesis
(Figure 3) with 67% having two or less episodes of vomiting
('major control'). For patients receiving LDPlac on first
exposure to chemotherapy total control was achieved in 11 %
(vs LDMet P = 0.004), major control in 25% (vsLDMet
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Figure 1 Mean number of episodes of vomiting (±95% CI)
during 1st and 2nd courses of chemotherapy for each group.
Treatment effects P<0.0001; treatment effect (1st period only),
P = 0.001; order effect P = 0.48; treatment vs order interaction,
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the total population who filled in diary cards. Figure 4 shows
that patients experienced more nausea after the second
course of treatment regardless of the anti-emetic treatment
(P = 0.0007).
Table II shows patient preference. Choice was not in-
fluenced by the order in which the treatments were given and
although more patients preferred LDMet this was not signi-
ficant. Seven patients (11.5%) receiving metoclopramide had
extrapyramidal reactions. One patient developed diabetes
requiring subsequent oral hypoglycaemic treatment. One
patient had severe oesophagitis and one reported nightmares.
Patients receiving LDMet spent significantly more hours
asleep than when receiving dexamethasone and lorazepam
only. The mean number of hours asleep for all LDMet
treatments was 11.7 (CI 10.6-12.8) while the mean number
of hours spent asleep for all LDPlac treatments was 8.7 (CI
7.8-9.6, P<0.001).
4 .
Figure 2 Mean number of hours of nausea (±95% CI) during
24 hours following 1st and 2nd courses ofchemotherapy for each
group. Treatment effect, P<0.0001; treatment effect (1st period
only), P = 0.002; order effect P = 0.57; treatment vs order inter-
action, P = 0.17.
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Figure 3 Per cent of patients in each group showing complete
control and major control of vomiting during first and second
courses. Major control-treatment effect, P<0.0002; treatment
effect (1st period only), P = 0.002; order effect, P = 0.10; treat-
ment vs order interaction, P = 0.30. Total control-treatment
effect, P<0.002, treatment effect (1st period only), P = 0.004;
order effect, P = 0.07; treatment vs order interaction, P = 1.0.
P = 0.002). Fewer patients had total or major control of
vomiting on receiving LDMet during their second chemo-
therapy course (43% and 21% respectively), although there
was no significant order effect or treatment vs order interac-
tion.
Figures 4 and 5 show the results of the analysis of the
diary cards completed during the 3-week period at home. The
mean number of days during which vomiting occurred after
the first course was 1.6 for group M/P and 1.95 for group
P/M with neither treatment being superior. The percentage of
patients experiencing delayed vomiting at any time after the
first course was 55% (16/29) after LDMet and 50% (13/26)
after LDPlac (X21 = 1.47, P>0.1). Of the total patients (M/P
and P/M) who experienced delayed emesis, vomiting con-
tinued after the first week in 21% (6/29), i.e 11% (6/55) of
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Figure 4 Mean number of days with vomiting (± 95% CI)
following 1st and 2nd courses of chemotherapy for each group.
Treatment effect, P = 0.44; treatment effect (1st period only),
P = 0.77; order effect, P = 0.36; treatment vs order interaction,
P= 0.48.
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Figure 5 Mean number of days with nausea (± 95% CI) follow-
ing 1st and 2nd courses of chemotherapy for each group. Treat-
ment effect, P = 0.76; treatment effect (1st period only), P = 0.64;
order effect, P = 0.0007; treatment vs order interaction, P = 0.79.
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Table II Preference of patients in each group for anti-emetic
regimen
Preferred Preferred Total
Patient group LDMet LDPlac (%)
Group M/P 17 12 30 (54%)
Group P/M 16 10 26 (46%)
Total 33 (59%) 23 (41%)
Treatment effect, P = 0.59; order effect, P = 0.18; treatment vs order
interaction, P = 0.71.
Discussion
This study shows that the combination of dexamethasone
and lorazepam gives major emetic control in about 25% of
patients. The regimen is simple to use and would probably be
useful for patients receiving moderately emetic chemotherapy
regimens without cisplatin. The addition of metoclopramide
significantly improves emetic control. Forty-five per cent of
patients had total and 67% major control when the triple
drug combination was given on first exposure to chemo-
therapy, compared with 11% total and 25% major using
dexamethasone and lorazepam only. The addition of metoc-
lopramide also reduced the degree of nausea in the first 24
hours of treatment. These results are similar to those
obtained in a double blind cross-over trial of high dose
metoclopramide with or without dexamethasone reported by
Allan et al. (1984). In 55 patients receiving 133 courses of
cisplatin chemotherapy, total control of emesis was recorded
in 43% of patients receiving metoclopramide plus dex-
amethasone, compared to 26% with metoclopramide plus
placebo. There was also a significant reduction in the dura-
tion of nausea. In this study oral dexamethasone alone was
as effective as oral dexamathasone plus oral metoclopramide
in limiting nausea and vomiting during the 20 days between
treatments. This is different to results recently reported by
Kris et al. (1989). They described emesis in the four days
post-chemotherapy in a group of patients who were all given
the same anti-emetic treatment during their first 24 h in
hospital and then randomised to receive oral placebo, oral
dexamethasone or oral dexamethasone with oral metoclop-
ramide. The oral dexamethasone with metoclopramide was
significantly better than single agent dexamethasone or
placebo during this assessment period (Kris et al., 1989). This
trial differs from the present trial in basic design, dose of
metoclopramide and duration of assessment.
The incidence of extrapyramidal reactions in this present
study was 11.5%. These have been described in as many as
20% of cases using various doses of metoclopramide (Strum
et al., 1982). In another study a much lower incidence of
extrapyramidal reactions was reported, at all dosages and
with all modes of administration (Kris et al., 1983). In their
large series of 452 patients, only 3% experienced extra-
pyramidal reactions, the incidence rising to 30% in patients
under 30 years of age. The same group have reported that
the addition of diphenhydramine and dexamethasone to
metoclopramide both improved emetic control and suppres-
sed the extrapyramidal side-effects (Kris et al., 1985). Extra-
pyramidal side-effects in themselves did not appear to influ-
ence patients' choice in the present study. Choice was usually
based on symptom control, general feeling of well being and
time taken at home to recover. It is likely that the amnesic
effect of lorazepam (Friedlander et al., 1983) reduced
patients' recall of their symptoms, reducing their perception
of the differences between the two arms. The timing of the
treatment to begin in the evening and carry on through the
night masked any sedation effect of lorazepam.
There was a significant increase in the number of days of
nausea experienced after all second courses regardless of the
anti-emetic treatment. This may have been due to a real
cumulative increase in this symptom with each course, or
possibly a better understanding of symptoms by the patients
with greater proficiency in filling in the diary card.
Anticipatory nausea and vomiting did not occur during these
first two courses of chemotherapy, nor was it expected, as a
median of four to five courses are usually needed for the
conditioned response to be established (Andrykowski, 1986;
Fetting et al., 1983).
Metoclopramide significantly contributes to anti-emetic
control and will remain an important component of anti-
emetic regimens until superior drugs become available. The
combination of metoclopramide in high dose with dex-
amethasone, with or without lorazepam, represents the best
available anti-emetic therapy for cisplatin containing regi-
mens, and is the standard against which new agents or
combinations should be tested.
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